🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 30 of 857 · Phase 3 first, then by program name

  1. Bel-sar

    Aura Biosciences

    Choroidal Melanoma

    phase 3 small molecule active

    1 trial

  2. Belantamab mafodotin

    GlaxoSmithKline

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  3. Beltavac Polymerized placebo. It is a saline solution without the allergenic extract, BELTAVAC with polymerized extract From Dermatophagoides

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis due to exposure of house dust mites

    phase 3 small molecule active

    1 trial

  4. Belzutifan, CABOZANTINIB , Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Advanced RCC with clear cell component

    phase 3 small molecule active

    1 trial

  5. Bemnifosbuvir (BEM)

    Atea Pharmaceuticals

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)

    phase 3 small molecule completed

    1 trial

  6. Bemnifosbuvir-Ruzasvir

    Atea Pharmaceuticals

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  7. Bemnifosbuvir-Ruzasvir (BEM/RZR)

    Atea Pharmaceuticals

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  8. Bemnifosbuvir/Ruzasvir Fixed Dose Combination (FDC), Sofosbuvir / Velpatasvir

    Atea Pharmaceuticals

    Chronic Hepatitis C Virus (HCV) Infection

    phase 3 small molecule active

    1 trial

  9. Bempedoic Acid + Ezetimibe Fixed-Dose Combination

    Esperion Therapeutics

    Hyperlipidemias

    phase 3 other completed

    1 trial

  10. Bempedoic acid 180 mg tablet

    Esperion Therapeutics

    Cardiovascular Diseases

    phase 3 small molecule completed

    1 trial

  11. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab terminated

    1 trial

  12. Bempegaldesleukin

    Nektar Therapeutics UK Limited

    Metastatic Head and Neck Cancer

    phase 3 small molecule terminated

    1 trial

  13. Bendamustine

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    1 trial

  14. Bendamustine 100 mg Powder for concentrate for Solution for Infusion, Truxima 100 mg concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, PREDNISONE BIOGARAN 20 mg, scored tablet, Cyclophosphamide Injection 500 mg., Doxorubicin 2 mg/ml Solution for Injection., Truxima 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Revlimid 5 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Revlimid 20 mg hard capsul

    AbbVie Deutschland GmbH & Co. KG

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  15. Bendamustine HCl

    Teva Pharma GmbH

    Non-Hodgkin's Lymphoma

    phase 3 small molecule completed

    1 trial

  16. Bendamustine hydrochloride

    Teva Pharma GmbH

    Non-Hodgkin Lymphoma

    phase 3 small molecule completed

    1 trial

  17. Benlysta 200 mg solution for injection in pre-filled pen.

    GlaxoSmithKline

    connective tissue diseases

    phase 3 small molecule active

    1 trial

  18. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.

    GlaxoSmithKline

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial

  19. Benralizumab

    AstraZeneca

    Asthma

    phase 3 mab completed

    1 trial

  20. Benralizumab

    AstraZeneca

    Chronic Obstructive Pulmonary Disease

    phase 3 mab completed

    1 trial

  21. Benralizumab 30 mg

    AstraZeneca

    Nasal Polyposis

    phase 3 mab terminated

    1 trial

  22. Benralizumab Placebo for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (APFS) for subcutaneous injection. Please refer to the IMPD documentation enclosed., Placebo, Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Hypereosinophilic Syndrome (HES)

    phase 3 small molecule active

    1 trial

  23. Benzyl penicillin

    United Therapeutics Europe Ltd

    Pneumonia

    phase 3 small molecule completed

    1 trial

  24. Bepirovirsen

    GlaxoSmithKline

    Chronic Hepatitis B

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources